CVRx In The News

CVRx® Announces that the First Two Patients were Treated in the Phase III Pivotal Trial Evaluating BAROSTIM THERAPY® for the Treatment of Heart Failure
June 6, 2016
CVRx® Announces Expedited Access Pathway Designation by FDA for Barostim Therapy® for the Treatment of Heart Failure in Order to Accelerate Access for US Patients
November 19, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference
May 27, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
May 26, 2015
CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Selected to be Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference
April 16, 2015
CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
March 17, 2015
CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Selected to be Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference
February 2, 2015
CVRx® Granted Humanitarian Device Exemption Approval from FDA for Barostim neo legacy™ Hypertension Therapy Device
December 16, 2014
CVRx® Granted CE Marking of the Barostim neo System™ for Conditional MRI Compatibility
December 11, 2014
CVRx® Announces First Successful Barostim Heart Failure Commercial Implants in Europe
October 7, 2014
CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure
September 29, 2014
CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank
September 22, 2014
Barostim Therapy™ Projected to be Cost-Effective in Treating Resistant Hypertension
January 7, 2014
CVRx® & DaVita Announce Strategic Partnership
November 5, 2013
CVRx® Closes $12 Million Additional Financing
October 30, 2013
CVRx®, Inc. Closes $29.6 Million Financing
July 10, 2013
Semmelweis Egyetem Kardiológiai Központ Completes First Implant of the Barostim neo™ Device for Hypertension.
May 15, 2013
CVRx® Launches European Registry to Monitor Hypertension Patients Treated with Barostim neo™ Device
July 2, 2012
CVRx® Receives CE Mark Approval and Introduces New Implantable Device for Hypertension, the Barostim neo™
August 25, 2011
Longer-Term Clinical Trial Findings Show Significant Reduction in Blood Pressure, Improvement in Heart Function with CVRx® Rheos® System
March 30, 2009
Clinical Data Presented at American Heart Association Meeting Show CVRx® Rheos® Therapy Improved Heart Structure and Function
November 11, 2008
Clinical Data Show CVRx® Rheos® Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
September 22, 2008
Clinical Data Show CVRx® Rheos® Therapy Improved Heart Structure and Function in Early-Stage Heart Failure Patients
September 22, 2008
CVRx®, Inc. Closes $84 Million Financing
July 29, 2008
Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx® Rheos® Hypertension Therapy
June 18, 2008
CVRx®, Inc. Receives CE Mark Approval for Rheos® Baroreflex Hypertension Therapy™ System
October 31, 2007
CVRx®, Inc. Closes $65 Million Financing
May 9, 2007
CVRx, Inc. Appoints Nadim Yared President and CEO
September 18, 2006
CVRx Receives Innovator of the Year Award
August 23, 2006
CVRx Raises Additional $30 Million
May 11, 2006
CVRx Raises Additional $30 Million
May 11, 2006

EUROPE:  The BAROSTIM NEO™ System is CE Marked and approved for sale for hypertension patients in the European Union (EU). It is also CE Marked and approved for sale for heart failure patients in the EU.

UNITED STATES:
CAUTION:  Investigational device. Limited by Federal (or United States) law to investigational use.
CAUTION:  Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal law for use in the treatment of resistant hypertensive patients implanted with the Rheos CSL leads.  The effectiveness of this device has not been demonstrated.

CANADA ONLY:  CAUTION: Exclusively for Clinical Investigations

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/